Abbott’s Metabolic Health Biowearable Gets ‘Extremely Positive’ UK Reception; Next Up, US Filing
“We’re so steeped in scientific and medical expertise that we never really learned how to talk to or with regular people,” says Abbott CEO Robert Ford.
Lingo, based on Abbott’s FreeStyle Libre diabetes management technology but targeted to the consumer market, works with a companion app to identify user habits that negatively impact their health and guide them in modifying behaviors accordingly. Olivier Ropars, division VP of Lingo Biowearables, discusses the company's recent UK launch and future plans.
You may also be interested in...
The continuous glucose monitoring space is expanding fast enough to accommodate two big players. Both Dexcom and Abbott recorded double-digit sales growth during the last quarter.
Abbott launched its first biowearable for consumers in the UK with plans to expand in Europe and the US. Analysts are optimistic about continued growth of Libre FreeStyle amid drivers such as CGM adoption by non-insulin users, expected 15-day sensor, streaming capability and integration with Tandem insulin pump.
CES 2022: Abbott CEO Robert Ford Announces New Biowearables Line For Consumers, Paving The Way From Measuring Glucose To Ketone, Lactate, Alcohol
Abbott announced today at CES 2022 it is developing a new line of consumer wearables, starting with a device to track ketones continuously, which is expected to launch in Europe this year.